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ABSTRACT
The role of the mRNA-binding protein human
antigen R (HuR) in stabilization and translation of
AU-rich elements (ARE) containing mRNAs is well
established. However, the trafficking of HuR and
bound mRNA cargo, which comprises a fundamen-
tal requirement for the aforementioned HuR func-
tions is only poorly understood. By administering
different cytoskeletal inhibitors, we found that the
protein kinase Cd (PKCd)-triggered accumulation
of cytoplasmic HuR by Angiotensin II (AngII) is
an actin-myosin driven process functionally
relevant for stabilization of ARE-bearing mRNAs.
Furthermore, we show that the AngII-induced
recruitment of HuR and its bound mRNA from
ribonucleoprotein particles to free and cytoskeleton
bound polysomes strongly depended on an intact
actomyosin cytoskeleton. In addition, HuR alloca-
tion to free and cytoskeletal bound polysomes
is highly sensitive toward RNase and PPtase and
structurally depends on serine 318 (S318) located
within the C-terminal RNA recognition motif
(RRM3). Conversely, the trafficking of the
phosphomimetic HuRS318D, mimicking HuR phos-
phorylation at S318 by the PKCd remained PPtase
resistant. Co-immunoprecipitation experiments
with truncated HuR proteins revealed that the
stimulus-induced association of HuR with myosin
IIA is strictly RNA dependent and mediated via the
RRM3. Our data implicate a microfilament depend-
ent transport of HuR, which is relevant for stimulus-
induced targeting of ARE-bearing mRNAs from
translational inactive ribonucleoprotein particles to
polysomes.
INTRODUCTION
The embryonic lethal abnormal vision (ELAV)-like
protein human antigen R (HuR) is a ubiquitously ex-
pressed member of a highly conserved RNA-binding
protein family functionally involved in the stabilization
of AU-rich element (ARE)-bearing mRNAs (1–3). In
addition to its originally described role as a mRNA sta-
bility factor, HuR functions have expanded to many other
aspects of mRNA processing including splicing,
polyadenylation, translation and modulation of miRNA
repression (4–6). HuR is implicated in key functions of
cells including proliferation, differentiation, apoptosis
and migration. Consequently, perturbations of physio-
logic HuR regulation play a causative role in many patho-
logic states (7–9). Although HuR is most abundantly
localized within the cell nucleus, its posttranscriptional
impact on target mRNA is tightly linked to the transloca-
tion of HuR from the nucleus to the cytoplasm and
backwards, which is structurally related to a HuR
nucleo-cytoplasmic shuttling (HNS) domain residing in
the basic hinge region of the protein (3,10). Published
data implicate that phosphorylation of HuR by different
protein kinases including checkpoint kinase 2 (11), cyclin-
dependent kinase 1 (12), protein kinase Ca (PKCa)( 13),
PKCb (14) and PKCd (15,16) can alter subcellular
localization of HuR and posttranscriptional effects by
HuR. Mapping of potential PKC phosphorylation
sites in HuR revealed several serines targeted by PKC
(13). Importantly, we found that PKCd through tandem
phosphorylation of different HuR domains coordinates
target mRNA binding within the nucleus and export
of HuR to the cytoplasm (16). Based on previously pub-
lished work, HuR distribution between the nucleus
and the cytoplasm is mediated by different transport re-
ceptors including transportin 1 and 2, importin a1 and
chromosome maintenance region 1 /exportin 1 (17–20).
However, the mechanisms underlying the cytoplasmic
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 trafﬁcking of HuR and its cargo mRNA are far less
understood.
The intracellular mRNA transport is mediated by
microﬁlaments together with their corresponding motor
proteins including kinesins, dyneins and myosins
(21–24). In contrast to microtubule-dependent transport,
which is assumed as the major trafﬁcking system for
mRNA in oocytes and axons, the actin-myosin system
seems more relevant in the short-distance mRNA trans-
port in non-neuronal cells (22). Importantly, the contact
of mRNA with the cytoskeleton in most cases is indirect
and mediated by RNA-binding proteins that target
speciﬁc cis-regulatory elements in the 30UTR of mRNA
as has been convincingly demonstrated for the interaction
of the Drosophila mRNA-binding protein Staufen with
oskar mRNA (25). Results from several studies suggest
an involvement of neuronal ELAV proteins in the micro-
tubule-mediated mRNA transport in axons (26,27). In
contrast, a comparable role of HuR in cytoskeleton-
guided mRNA transport has not been shown so far.
Here, we aimed to analyze the functional role of cytoskel-
etal elements in the AngII-induced nucleo-cytoplasmic
HuR redistribution in human renal mesangial cells
(HMC). We unveiled that the actin–myosin cytoskeleton
is essential for the nuclear export and transport of HuR to
the translationally active polysomes. We furthermore
demonstrate that myosin IIA is able to associate with
HuR only if phosphorylated at S318 via the C-terminal
RRM3. Our data suggest that dynamic interactions with
the cytoskeleton play a critical role in the spatio-temporal
control of mRNA transport and translation by the
ubiquitous mRNA-binding protein HuR.
MATERIALS AND METHODS
Reagents
Latrunculin-A and colchicine were obtained from
Calbiochem (Schwalbach, Germany). Actinomycin D
(from Streptomyces species), human angiotensin II,
blebbistatin, 40,6 0-diamidino-2-phenylindole (DAPI),
phalloidin-rhodamine, MG-132, the anti-Flag antibody
and a secondary rhodamin coupled anti-mouse antibody
were purchased from Sigma-Aldrich (Deisenhofen,
Germany). Ribonucleotides and modifying enzymes were
from Life Technologies (Karlsruhe, Germany). Antibodies
raised against HuR, histone deacetylase-1 (HDAC1),
c-myc, anti-rabbit and anti-mouse horseradish peroxidase
linked immunoglobulin G (IgG) were purchased from
Santa Cruz Biotechnology (Heidelberg, Germany).
Antibodies raised against green ﬂuorescent protein
(GFP), a-actinin, myosin IIA, phospho-p38 MAPK and
p38 MAPK were obtained from Cell Signaling (Frankfurt
am Main, Germany). The secondary Alexa-Fluoro
488-coupled and Cy3 antibodies were from Molecular
Probes (Karlsruhe, Germany). Protein G sepharose, the
ECL system and Hyperﬁlm were from GE Healthcare
(Mu ¨ nchen, Germany). All cell culture media and supple-
ments were purchased from Life Technologies (Karlsruhe,
Germany).
Cell culture
Human primary mesangial cells (HMC) were isolated
from collagenase IV-treated human glomeruli and
cultivated as described previously (28). Serum-free
preincubations were performed in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 0.1mg of fatty acid-
free bovine serum albumin/ml. For experiments, HMC
were grown to 80% conﬂuency before stimulated.
RNA interference
Genesilencing wasperformedbyusingtheFlexiTube small
interfering RNA (siRNA) for human non-muscle myosin
IIA heavy chain 9 (siRNA-MYH9) from Qiagen (Hilden,
Germany), HuR-speciﬁc siRNAs from Santa Cruz
Biotechnology and a control siRNA from Dharmacon
(Fermentas, St. Leon-Rot, Germany). siRNA transfection
of subconﬂuent HMC was performed by using the
Oligofectamine reagent (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instructions.
Separation of polysomes from translational inactive
ribonucleoprotein particles
Trypsinized cells were collected by centrifugation for 5min
at 5000g at 4 C before cell pellets were mixed with two
volumes of ice-cold lysis buffer [20mM HEPES, 250mM
sucrose, 250mM KCl, 5mM MgCl2, 2mM dithiothreitol,
1mg/ml heparine (pH 7.5)] and homogenized by freezing
and thawing in liquid nitrogen followed by centrifugation
at 4000g for 10min at 4 C. Supernatants were supple-
mented with Triton X-100 (ﬁnal 1%) and 40U/ml
RNaseOUT (Invitrogen, Karlsruhe, Germany) and equal
volumes loaded (0.5ml) onto a sucrose cushion (1M) and
polysomes isolated by centrifugation at 100 000g for 2h at
4 C. Polysomal pellets were dissolved in polysomal lysis
buffer [10mM Tris–HCl, 100mM NaCl, 10mM EDTA,
1% SDS (pH 7.4)], whereas the supernatants were further
centrifuged at 300000g for 3h at 4 C for isolation of
postpolysomal messenger ribonucleoproteins particles
(mRNP) fractions, which were also dissolved in polysomal
lysis buffer. To control the relative purity of the separated
fractions, aliquots from both fractions were monitored by
optical density measurement (A254).
Polysomal fractionation
The isolation of different polysomal fractions was
performed by using a protocol published by Hovland
et al.( 29). Thereby, cells were homogenized in 1ml of
ice-cold lysis buffer I [10mM Tris–HCl (pH 7.6), 0.25M
sucrose, 25mM KCl, 5mM MgCl2, 0.5mM CaCl2, 0.5%
NP40] and cell lysates sedimented by centrifugation at
1000g for 5min with supernatants contain free polysomal
fractions. The remaining pellet including cell nuclei,
insolube cell membranes and cytoskeletal proteins was
washed with lysis buffer I before cytoskeletal-bound poly-
somes (CBP) were isolated by the addition of lysis buffer
II [10mM Tris–HCl (pH 7.6), 0.25M sucrose, 130mM
KCl, 5mM MgCl2, 0.5mM CaCl2, 0.05% NP40].
Lysates were again centrifugated at 2000g for 5min to
separate CBP accumulated in the supernatants, from
2 Nucleic AcidsResearch, 2013membrane-bound polysomes (MBP), which were enriched
in the pellets after being resuspended in buffer III contain-
ing 10mM Tris–HCl (pH 7.6), 0.25M sucrose, 25mM
KCl, 5mM MgCl2, 0.5mM CaCl2, 0.5% NP40 and
0.5% deoxycholate. After incubation for 10min on ice,
MBPs were collected by a ﬁnal centrifugation step at
3000 g. The activity of lactate dehydrogenase, which is
preferentially detected in the fraction of free polysomes,
was quantiﬁed by using the CytoTox96 Nonradioactive
Cytotoxicity Assay (Promega, Mannheim, Germany)
and normalized to protein concentrations of correspond-
ing samples.
PPtase and RNase treatments of polysomal fractions
To assess the possible role of RNA and phosphorylation
in polysomal HuR distribution, a portion (0.3ml) of the
cell homogenates, which had been lyzed in buffer I, before
centrifugation were incubated with 1U protein phosphat-
ase 1 (Roche, Mannheim, Germany) for 30min at 30 C
before the polysomal fractionation was continued.
Correspondingly, another portion of the cell homogenate
was treated with 10mg RNase A/ 25U T1 for 10min at
37 C and, subsequently, polysomal fractions were
prepared as described earlier in the text.
Construction of eukaryotic expression plasmids
The plasmid pEGFP-PKCd containing a C-terminal
fusion of full-length human PKCd was generated accord-
ing to a strategy described previously (30).
Flag-tagged recombinant wild-type HuR (pCMV-Flag-
HuRwt) was generated by subcloning the pQE30-His-
wild-type HuR plasmid DNA into the eukaryotic
pCMV-Flag-N3 expression vector as described previously
(15). The plasmid pCMV-Flag-Ser318DHuR, which
encompasses a cDNA encoding a phosphomimetic HuR
mutant with a serine to aspartate substitution at amino
acid position 318, was generated as described previously
(31), and pCMV-Flag-Ser318AHuR was generated as
described previously (16). Plasmids bearing wild-type or,
alternatively, different c-myc-tagged HuR deletions were
constructed by subcloning a cDNA fragment containing
the coding region of HuR plus the myc-tag into HindIII/
EcoRI cut pcDNA3.1 vector (Invitrogen) by using the
plasmid pTet-Myc-HuR as a template (32) and are
further described in Supplementary Methods. Point muta-
tions and proper in-frame insertion of cDNAs was proven
by DNA sequencing. HMC were transiently transfected
with different c-myc-tagged cDNA constructs by using
the Lipofectamine reagent (Invitrogen). Transfection of
pCMV-Flag constructs was done using Effectene
(Qiagen, Hilden, Germany) by following the manufac-
turer’s protocol.
Immunoprecipitation-qRT-PCR analysis
HuR-bound mRNA was isolated by Immunoprecipitation
(IP)-qRT-PCR analysis (pull-down RT assay) as reported
previously (15).
RNA isolation and RT-PCR analysis
Total RNA was extracted from whole-cell lysates by using
the Tri-reagent (Sigma-Aldrich). First strand cDNA was
synthesized using random hexamer primer (Fermentas) and
Superscript reverse transcriptase (Life Technologies).
Primers used for PCR are listed in the Supplementary
Methods section. Semiquantitative PCRs were performed
with 28 cycles (30s at 95 C, 30s at 60 C and 60s at 72 C).
Western blot analysis
Nuclear and cytoplasmic extracts from HMC were
prepared following to a protocol described by Schreiber
et al.( 33). To conﬁrm an equal loading of nuclear or
cytoplasmic proteins, the blots were additionally probed
with either an antibody raised against HDAC1 or with a
b-actin speciﬁc antibody. Total protein lysates were
prepared by standard procedures. Proteins were detected
by using speciﬁc primary and the appropriate secondary
antibodies and visualized with chemiluminescence using
an ECL system from GE Healthcare.
IP
IP was performed as described previously (16) and is
described in more detail in the Supplementary Methods
section.
Blot overlay assay
Blot overlay was performed by using a modiﬁed protocol
from Co ˆ te ´ and Richard (34). For blot overlay assay
experiments, 300mg of total cell lysates derived from un-
treated HMC were subjected to myosin II IP as described.
Subsequently, the myosin IIA-precipitated proteins
were separated by SDS–PAGE and transferred to
polyvinylidene diﬂuoride membranes. After blocking, the
membrane was incubated for 16h at 4 C with total cell
lysates (0.2mg/ml) derived from vehicle- or AngII-treated
HMC overexpressing either c-myc tagged HuRwt (c-myc-
HuRwt) or c-myc-tagged HuRHinge (c-myc-
HuRHinge) proteins. After several washing steps with
TBST, myosin-bound c-myc fusion proteins were detected
by immunoblotting by using an anti-c-myc speciﬁc
antibody.
Fluorescence microscopy
Cells were grown on coverslips at 60–80% conﬂuence and
rendered serum-free for 16h before stimulated for the
indicated periods. Immediately following treatment, cells
were rinsed once with phosphate buffered saline (PBS)
and subsequently ﬁxed for 20min at RT with 4%
paraformaldehyde in PBS, before cells were blocked and
permeabilized in 2% BSA plus 0.1% Triton X-100 (PBS)
at RT. Subsequently, the ﬁxed cells were stained with the
indicated primary antibodies for 30min at RT, before cells
were incubated with a secondary Alexa Fluor 488-or
rhodamine-coupled antibody for 1h at RT. F-actin was
visualized with rhodamine-conjugated phalloidin, and cell
nuclei were counterstained with DAPI before mounted on
slides by using Fluoromount-G (Southern Biotech,
Eching, Germany).
Nucleic Acids Research, 2013 3Cells were imaged with a inverted confocal microscope
(LSM 510) from Zeiss (Go ¨ ttingen, Germany) by using a
Plan Apochromat 40 /1.4 oil-immersion objective and
488, 543 and 633nm laser lines, respectively. Image acqui-
sition was performed with the ZEN2009 Light Edition
software (Carl Zeiss, Inc).
Statistical analysis
Results are depicted as mean values±standard deviation
(SD). The data are presented as x-fold induction
compared with untreated conditions (*) or to stimulated
values (#). Statistical analysis was performed using
Student’s t-test and analysis of variance with the
Bonferroni multicomparison test. P<0.05 (*), (#) or
P<0.01 (**), (##) or P<0.005 (***), (###) were
considered signiﬁcant.
RESULTS
The stimulus-dependent increase in cytoplasmic HuR by
AngII depends on the actin-myosin cytoskeleton
To address the functional role of the cytoskeleton in HuR
shuttlinginducedbythevasoactivehormoneAngIIinrenal
HMC (15,16), we tested the effects of two well-established
cytoskeleton inhibitors speciﬁcally interfering with the in-
tegrity of microﬁlaments (latrunculin A) or microtubules
(colchicine). Western blot analysis revealed a strong
increase in cytoplasmic HuR abundance on stimulation
with AngII (0.1mM) (Figure 1A, left panel). Interestingly,
a short preincubation of cells for 30min with latrunculin A
(0.1mM), which prevents F-actin polymerization, com-
pletely inhibited cytoplasmic HuR accumulation by
AngII, whereas colchicine (0.1mg/ml) had no effects on
cytoplasmic HuR levels (Figure 1A, left panel). In
contrast, the nuclear and total content of HuR remained
unchanged, independent of which inhibitor was applied
(Supplementary Figure S1). As actin-dependent transport
of mRNPs in many cases depends on the molecular motor
protein myosin (22), we furthermore tested whether inhib-
ition of myosin activity could similarly impair the cytoplas-
mic HuR accumulation by AngII. For this purpose, we
tested the effects of blebbistatin (5mM), a small molecule
inhibitor with a reported high selectivity toward the non-
muscle myosin IIA ATPase (35). To achieve a maximal
inhibitory effect on enzymatic activity, blebbistatin
instead of 30min, was preincubated for 4 and 16h, respect-
ively.Thereby, weobserved signiﬁcant inhibitory effects on
AngII-induced HuR by blebbistatin at both incubation
periods but most clearly seen at 16h (Figure 1A, right
panel). Interestingly, in contrast to its inhibitory effect on
the AngII-induced cytoplasmic HuR accumulation,
blebbistatin increased the content of cytoplasmic HuR
when given alone, and this effect was most clearly seen at
16h (Figure 1A, right panel). We assume that the stimula-
tory effect on HuR shuttling by blebbistatin is independent
of myosin inhibition and likely due to a drug-dependent
induction of stress responses as indicated by the rapid
increase in p38 MAPK phosphorylation (Supplementary
Figure S2A). Importantly in HMC, the p38 MAPK
pathway is functionally irrelevant for cytoplasmic HuR
accumulation by AngII (15). In addition, colchicine that
had no inhibitory effect on the AngII-induced nucleo-
cytoplasmic HuR shuttling (Figure 1A), clearly reduced
the cytoplasmic HuR accumulation by blebbistatin
(Supplementaryl Figure S2B), thus indicating that the
blebbistatin-triggered HuR redistribution depends on a
microtubuli-dependent transport mechanism. To verify
the results from pharmacological myosin inhibition, we
additionally tested the impact of myosin by siRNA deple-
tion.Wedecidedtodepletetheheavychain9ofnon-muscle
myosin IIA (MYH9), as it is known to mediate many
cellular processes by myosin IIA (36). In agreement with
the long-term inhibition of cytoplasmic HuR accumula-
tion, we observed a total blockade in cytoplasmic HuR
accumulation (Figure 1B). In contrast, the blebbistatin-
induced cytoplasmic HuR accumulation observed at 16h
was not affected by myosin IIA depletion (Supplementary
Figure S2C), which further substantiates our ﬁnding that
the stimulatory activity of HuR export by blebbistatin is
independent of myosin IIA. As phosphorylation and sub-
sequent export of nuclear HuR to the cytoplasm in
response to the octapeptide AngII depends on a prior
PKCd import to the nucleus (15), we furthermore tested
whether the inhibitory effects of latrunculin A on cytoplas-
mic HuR accumulation is possibly indirect and due to an
inhibition of PKCd translocation. For this purpose, we
monitored the cytoplasmic HuR accumulation after
ectopical expression of PKCd (16). Notably, HMC dis-
played a clear increase in cytoplasmic HuR content 24h
after transient transfection of GFP-PKCd, whereas cells
that were co-treated in the presence of latrunculin
A showed a strong reduction in cytoplasmic HuR levels.
As expected, colchicine had no effect on cytoplasmic HuR
levels induced by PKCd overexpression (Figure 1C).
Concordant with the data from Western blotting,
the visualization of intracellular HuR distribution by
confocal microscopy shows an intense staining of HuR
exclusively in the nuclei of untreated HMC but a strong
extension of HuR staining to cytoplasmic regions in cells
that were exposed to AngII for 2h (Figure 2A and B).
Notably, in contrast to the results from western blot
analysis, the nuclear HuR signal was strongly diminished
on AngII treatment (Figure 2A and B). Concomitant with
the strong disruption of microﬁlaments, the AngII-
induced increase in cytosolic HuR was totally impaired
if cells were pretreated with latrunculin (Figure 2). The
strong shrinkage that was observed in many cells and
nuclei after administration of latrunculin is expected and
results from the impaired tension of the cytoskeleton after
disruption of F-actin ﬁlaments (Figure 2A). Similar to
latrunculin A, blebbistatin impaired cytoplasmic HuR
abundance by AngII when used for longer preincubations
(Figure 2). Importantly, none of these inhibitors had any
effect on the high basal HuR abundance in cell nuclei
(Supplementary Figure S3).
Modulatory effects on HuR-triggered mRNA expression
by cytoskeletal inhibitors
Next, we tested whether an inhibition of cytoplasmic HuR
by microﬁlament inhibitors is functionally relevant for the
4 Nucleic AcidsResearch, 2013Figure 1. AngII-induced and PKCd-mimicked cytoplasmic HuR accumulation depend on the actin-myosin cytoskeleton. (A, left panel). Cells were
serum starved for 16h before stimulated for 2h with vehicle ( ) or AngII (0.1mM) without or with either latrunculin A (Lat. A) or colchicine
(Colch.) as indicated. Both inhibitors were preincubated for 30min before the addition of AngII. Protein lysates (20mg) of cytoplasmic fractions were
subjected to SDS–PAGE and successively immunoblotted with anti-HuR and anti-b-actin antibodies. (A, right panel). Western blot analysis
demonstrating a time-dependent inhibitory effect of blebbistatin on cytoplasmic HuR levels. HMC were treated for the indicated time points
with blebbistatin (Blebbistat.) before cells were additionally stimulated for 2h with vehicle ( ) or AngII as indicated. Data summerize densitometric
analysis of cytoplasmic HuR relative to b-actin levels and represent means±SD. (n=3). **P 0.01, ***P 0.005 compared with control.
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(continued)expression of the HuR target mRNAs COX-2, cyclin
A and cyclin D1, which is similarly increased by AngII
via HuR-dependent stabilization of corresponding
mRNAs (16). To induce COX-2 mRNA, cells were pre-
treated with TNFa and IL-1b (both at 2nM) for 16h
before AngII was administered for further 2h. In full ac-
cordance with our previous ﬁndings (16), AngII caused a
substantial increase in cytokine-induced levels of COX-2,
cyclin A and cyclin D1 encoding mRNAs (Figure 3A). The
increased abundance of these mRNAs by AngII was
totally blocked when cells were treated in the presence of
latrunculin A or blebbistatin (Figure 3A). Furthermore,
monitoring the time-course of mRNA decay with
actinomycin D, demonstrated that the stimulatory
effects of AngII on the cytokine-induced COX-2 mRNA
were strongly antagonized by both inhibitors (Figure 3B).
In particular, AngII caused a substantial raise in COX-2
mRNA stability, increasing the half-life from almost 3 to
Figure 1. Continued
##P 0.01 and ###P 0.005 versus AngII-treated conditions. (B). Serum starved HMC were transfected for 72h with duplex siRNA of human
myosin heavy chain 9 of myosin IIA (siRNA-MYH9) or with control siRNA (siRNA-control). After transfection, cells were serum starved for 16h
before treated for further 2h with vehicle or with AngII (0.1mM). Thereafter, cells were lyzed for either total or cytoplasmic and nuclear protein
extracts. The levels of myosin IIA and HuR protein in total cell lysates and cytoplasmic extracts were monitored by western blot analysis with
corresponding antibodies. Nuclear fractions are characterized by the high contents of HDAC1, which was not detectable in cytoplasmic cell lysates.
Cytoplasmic extracts are characterized by positive b-actin staining. (C). HMC cells were transfected with a GFP-tagged PKCd expression plasmid
(PKCd-GFP), or with the corresponding empty vector (mock transfected). 72h after transfection, cells were starved for 16h and preincubated for
additional 30min with latrunculin A or with colchicine as indicated. Thereafter, duplicates were extracted for either total, nuclear or cytoplasmic
extracts, respectively. The contents of GFP-tagged PKCd and HuR in the different fractions were monitored by Western blot analysis using
corresponding antibodies. To correct for variations in protein loading, the blots were stripped and additionally monitored for b-actin (cytoplasmic)
or HDAC1 (nuclear) contents. The data shown are from a single experiment representative for two independent experiments giving similar results.
Figure 2. Disruption of the actin-myosin cytoskeleton impairs nucleo-cytoplasmic HuR shuttling by AngII. (A). Confocal microscopy was applied to
visualize changes in the actin–myosin cytoskeleton by chemical inhibitors and nucleo-cytoplasmic redistribution of HuR. Serum starved HMC were
treated for 2h with vehicle or AngII (0.1mM) in the absence or presence of either latrunculin A (0.1mM) or blebbistatin (5mM), which
were preincubated for 30min (Lat. A) or 4h (Blebbistat.), respectively, before the addition of AngII. After ﬁxation and permeabilization, cells
were stained with an anti-HuR antibody and subsequently with the Alexa-Fluoro 488 coupled (green) secondary antibody. F-actin was visualized
with rhodamine-conjugated phalloidin with merged pictures showing HuR plus F-actin staining. Cell nuclei were visualized by staining with DAPI
(40,60-DAPI). Bars, 20mm. (B). Cells were treated as in (A), but simultaneously immunostained for myosin IIA (green), HuR (red) using either Alexa-
Fluoro 488 or Cy3 coupled secondary antibodies. Additionally, cells were stained with DAPI (blue). Bars, 25mm. Data shown are from a single
experiment representative of two repeats giving similar results.
6 Nucleic AcidsResearch, 2013>8h when compared with GAPDH mRNA levels (15).
Importantly, the AngII-evoked increase in COX-2
mRNA half-life signiﬁcantly dropped from  8t o 2h
if blebbistatin was additionally applied to the cells
(Figure 3B, left panel). Correspondingly, a strong reduc-
tion in COX-2 mRNA half-life (from  8hto 2.5h) was
observed if cells were treated in the presence of latrunculin
A( Figure 3B, right panel). In contrast, the half-life of
COX-2 mRNA was below 3h when cells were treated
with either of the mentioned inhibitors alone (Figure 3B,
open circles). Concomitant with their strong suppressive
effects on COX-2 mRNA-stability, both compounds
totally impaired HuR binding to COX-2 mRNA as
analyzed by pull-down RT-PCR assay (Figure 3C).
AngII-induced association of HuR with free and
cytoskeletal bound polysomes is impaired after
microﬁlament inhibition
An increase in cytoplasmic HuR in many cases is func-
tionally equivalent with a recruitment of HuR-bound
target mRNAs to the translation apparatus. Three major
sites of translation can be distinguished including free
cytoplasmic polysomes (FP), CBP and, ﬁnally, polysomes
associated with the endoplasmatic reticulum (MBP) (21).
Here, we explored whether microﬁlament disruption
would also affect the stimulus-induced HuR translocation
to distinct polysomal aggregations by using polysomal
fractionation. Western blotting revealed that the AngII-
induced accumulation of HuR to FP and CBP, the latter
fraction of which is characterized by high a-actinin levels,
is totally impaired in the presence of latrunculin A or
blebbistatin (Figure 4A). In contrast, the content of
b-actin mRNA, which characteristically can be found in
both polysome fractions, remained unchanged independ-
ent of which inhibitor was applied (Figure 4A, upper
panel). In addition to the lack of a-actinin, the high
activity of the cytosolic marker enzyme lactate dehydro-
genase within free polysomal fractions conﬁrmed an
adequate separation of this fraction (Supplementary
Figure S4A). In contrast, HuR was not detectable in the
fraction of MBP (Figure 4A), which is characterized by
the strong expression of the acetylcholine receptor a
(AchRa)( 29). In addition, we tested whether the effects
on polysomal HuR distribution by both microﬁlament in-
hibitors are functionally redundant with changes in the
polysomal loading of COX-2 mRNA. Again, to achieve
transcriptional induction of COX-2, cells were stimulated
for 16h with a cytokine mix before AngII was added for
further 2h. Concomitant with the observed changes
in polysomal HuR distribution, COX-2 mRNA was
exclusively detected in fractions of FP and CBP from
Figure 3. Microﬁlament inhibitors suppress the AngII-mediated
increase in COX-2 expression by preventing HuR binding to the cor-
responding mRNA. (A). HMC cells were treated for 2h with either
vehicle ( ) or with AngII, or together with different microﬁlament
inhibitors as indicated. Inhibitors were preincubated for 30min
(Lat.A) or 4h (Blebbistat.) before the addition of AngII. To achieve
transcriptional induction of different HuR target genes, cells were
stimulated for 16h with a cytokine mix containing IL-1b and TNFa
(both at 2nM) before AngII treatment. Steady-state mRNA levels of
COX-2, cyclin A and cyclin D1 were quantiﬁed by qRT-PCR using
b-actin as a normalization control. Results are depicted as relative
mRNA levels (%) in comparison with cytokine-stimulated conditions
(vehicle), which were set to 100% and are means±SD (n=3).
**P 0.01, ***P 0.005 compared with cytokine-induced conditions
##P 0.01 and ###P 0.005, compared with cytokine plus AngII-
treated conditions. (B). Reduction of AngII-mediated stabilization of
cytokine-triggered COX-2 mRNA by blebbistatin (left panel) or
latrunculin A (right panel). Quiescent HMC were treated for 20h
with a cytokine mixture containing IL-1b and TNFa (both at 2nM)
before the administration of Act D, which was added 30min before
AngII (ﬁlled triangles). Importantly, the indicated cytoskeletal inhibi-
tors were given 4.5h before the addition of AngII and remained for the
indicated times with vehicle (open circles) or with 0.1mM AngII (open
squares) before cells were harvested and extracted for total cellular
RNA. Steady-state mRNA levels of COX-2 were determined by
qRT-PCR using b-actin mRNA as a normalization control. Graphs
show means±SD (n=3) and depict the percentage of remaining
COX-2 mRNA levels compared with the content of steady-state
Figure 3. Continued
COX-2 mRNA measured immediately before the addition of Act D
(0h). (C). HMC were treated similarly as described in (A) before
total cell lysates were assayed by IP using an anti-HuR antibody
(gray bars), or the same amount of isotypic IgG (open bars). HuR-
bound COX-2 mRNA was determined by pulldown RT assays. Data
shown are means of two independent experiments and are depicted as
fold induction versus cytokine-treated cells.
Nucleic Acids Research, 2013 7Figure 4. HuR recruitment to free and cytoskeleton-bound polysomes by AngII is impaired after microﬁlament disruption and depends on HuR
phosphorylation. (A). HMC were treated for 2h either with vehicle ( ) or with AngII (0.1mM) in the absence or presence of either latrunculin A
(0.1mM) or blebbistatin (5mM). Latrunculin was preincubated for 30min and blebbistatin for 4h before the addition of AngII. HMC were subse-
quently subjected to sequential detergent and salt extraction to release FP, CBP and MBP as described in ‘Materials and Methods’ section. Similar
amounts of proteins corresponding to the different polysomal fractions were subjected to SDS–PAGE and successively immunoblotted with
antibodies against HuR or a-actinin, the latter of which was used as a marker for cytoskeletal cell fractions. Additionally, RT-PCR products
corresponding to a-actin and AchRa mRNAs were used as speciﬁc markers of cytoplasmic (b-actin) or membrane bound proteins (AchRa). Data are
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(continued)cytokine-treated cells costimulated with AngII
(Figure 4B). By contrast, polysomal COX-2 mRNA was
neither detectable in control cells that had only been
treated with a cytokine mix nor in cells that were
costimulated with latrunculin or blebbistatin, thus
indicating that the increase in the polysomal COX-2
mRNA content is mainly triggered by AngII
(Figure 4B). Conversely, the amount of nonpolysomal
COX-2 mRNA, which is restricted to the nucleus, was
highest in cytokine-treated cells either treated in the
absence or presence of latrunculin or blebbistatin, respec-
tively (Supplementary Figure S4B).
HuR recruitment to free and cytoskeleton bound
polysomes by AngII is phosphorylation and RNA
dependent
As HuR phosphorylation at S318 by PKCd is implicated
in the AngII-induced and constitutive binding and stabil-
ization of ARE mRNAs by HuR (16,31), we assessed
whether the AngII-induced HuR recruitment to poly-
somes depends on phosphorylation events and/or on the
presence of RNA. To this end, polysomal fractions were
isolated from alkaline phosphatase or RNase A/T1-treated
cell lysates from AngII-stimulated HMC. To conﬁrm the
efﬁciency of phosphatase treatment, the phosphorylation
status of immunoprecipitated HuR was monitored by a
phospho-Ser-PKC substrate-speciﬁc antibody (Figure 4A,
right panel, +PPtase). Accordingly, RNase A/T1 effects
were conﬁrmed by semiquantitative PCR and agarose
gel electrophoresis (Figure 4A, right panel, +RNase).
Interestingly, the high content of HuR in FP and CBP
triggered by AngII totally disappeared if polysome
subfractions were isolated from phosphatase (+PPtase)
or RNase treated (+RNase) cell lysates (Figure 4A,
middle panel). Based on the observation that treatment
of cell extracts with either RNase or PPtase eliminated
HuR from all polysomal fractions, we reasoned that
probably proteasomal degradation could be responsible
for the disappearance of HuR, as ubiquitin-mediated pro-
teolysis of HuR resambles an additional paradigm of HuR
regulation (37,38). To address this issue, before separating
polysomal fractions, cell lysates were pretreated with
MG-132, a broad spectrum proteasome inhibitor before
either RNase or PPtase was applied to cell extracts.
Interestingly, preincubation of cell lysates with MG-132
restored a HuR accumulation to the fraction of FP even
if RNase or PPtase was applied (Supplementary
Figure S4C). By contrast, the co-sedimentation of HuR
with CBPs was still fully impaired by RNase and PPtase
(Supplementary Figure S4C). These data indicate that
RNase or PPtase treatment leads to the dissociation of
HuR from CBP and FP to soluble cytoplasmic fractions
where the HuR protein is a target of rapid proteasomal
degradation. The fact that MG-132 did only rescue HuR
if dissociated from FP strongly indicates that the FP
fraction additionally contains soluble cytoplasmic
proteins. To further verify the assumption that HuR dis-
tribution to both polysomal fractions may critically
depend on the presence of RNA and on the phosphory-
lation status of HuR, we used a phosphomimetic Ser 318
to Asp mutated Flag-tagged HuR protein (pCMV-
FlagS318DHuR), which in contrast to wild-type HuR
(pCMV-FlagHuRwt) displays a high constitutive RNA
binding to several ARE mRNAs (31). HMC transfected
with Flag-tagged HuRwt showed the same dramatic
changes in HuR distribution by AngII as endogenous
HuR (Figure 4C). Importantly, a similar stimulus-depend-
ent accumulation of Flag-tagged HuR in polysomes was
observed in pCMV-FlagS318DHuR transfectants, and,
notably, the co-sedimentation of phosphomimetic HuR
protein with both polysomal fractions was insensitive
toward phosphatase treatment but still RNase sensitive
(Figure 4C). Conversely, a phosphorylation deﬁcient
HuR chimera (pCMV-Flag-S318AHuR) was refractory
to AngII-mediated recruitment to polysomes (Figure 4C).
Similar to endogenous HuR, none of the HuR fusion
proteins were detected in MBP subfractions (Figure 4C).
These data clearly implicate that the RNA-bound state of
HuR, which is triggered by PKCd-dependent phosphory-
lation at S318, is critical for HuR recruitment to free and
cytoskeleton-bound polysomes.
AngII-induced HuR association with polysomes depends
on the actin-myosin cytoskeleton
The redistribution of target mRNA from non-polysomal
mRNPs to translational active polysomes is a non-random
path, which reﬂects a general increase in translational
activity of an mRNA. To examine whether the temporal
shift in HuR and its bound target mRNA from mRNPs to
translationally active polysomes is affected by disrupting
the actin-myosin cytoskeleton, we used sequential ultra-
centrifugation on sucrose cushion, which enables
Figure 4. Continued
representative for two independent experiments giving similar results. (A, right upper panels). Before the isolation of polysomal subfractions, cell
lysates were additionally treated with protein phosphatase 1 (+PPtase) or, alternatively, with RNaseA/T1 (+RNase) as described in ‘Materials and
Methods’ section. To validate the accuracy of the treatment, a portion from PPtase-treated cell extracts was subjected to HuR-IP, and
phosphorylated HuR levels were monitored by western blot analysis using a p-Ser-PKC substrate antibody (right panel). Accordingly, one
portion of the RNase-treated cell homogenates was subjected to total RNA isolation and the presence of b-actin mRNA was subsequently
analyzed by RT-PCR (right panel). (B). HMC were preincubated for 16h with a cytokine mix consisting of IL-1b and TNFa (both at 2nM)
before addition of AngII (+AngII) for 2h in the absence ( ) or presence of the indicated cytoskeletal inhibitors, which were given 4h before the
administration of AngII. Subsequently, different polysomal fractions were separated as described in (A) before RNA from these fractions was
harvested and steady-state levels of COX-2 mRNA measured by qRT-PCR. Values show stimulus-dependent changes in COX-2 mRNA contents
related to total cytokine-induced COX-2 mRNA levels measured in duplicates. (C). HMC were transfected either with pCMV-Flag-HuRwt (left
panel) or with pCMV-Flag-S318DHuR (middle) or, alternatively, with pCMV-Flag-S318AHuR (right panel) for 24h before treated without ( )o r
with AngII (0.1mM) for 2h. Subsequently, cells were lyzed and before polysomal fractionation, similar portions of lysates were treated with either
protein phosphatase 1 (+PPtase) or RNase (+RNase). Thereafter, different polysomal fractions (FP, CBP, MBP) were isolated and analyzed for HuR
enrichment by Western blot analysis.
Nucleic Acids Research, 2013 9fractionation of free mRNPs devoid of polysomes from
polyribosomes. Western blot analysis of both fractions
identiﬁed that in unstimulated HMC, HuR is exclusively
detectable in the fraction of non-polysomal RNPs
(RNPs), whereas stimulation of cells with AngII-induced
co-sedimentation of HuR with polysomal fractions con-
comitant with a reduction of HuR in the corresponding
RNP fraction (Figure 5A, left panel). As a control, dis-
ruption of polysome assembly after addition of EDTA to
cell lysates, resulted in an almost total loss of HuR in the
polysomal fraction (Figure 5A, right panel). Consistently,
the AngII-induced shift in HuR attachment from RNPs
to polysomes was prevented when cells were stimulated in
the presence of latrunculin or blebbistatin (Figure 5A, left
panel). Similar inhibitory effects were observed after
transfection of MYH9-speciﬁc siRNAs (siRNA-MYH9)
(Figure 5B, left panel). A similar stimulus-dependent
shift in HuR distribution was observed with Flag-tagged
wild-type HuR (Figure 5B, right panel). In addition to the
changes in HuR distribution, AngII treatment caused a
strong relocalization of cytokine-induced COX-2 mRNA
from non-polysomal RNPs to polysomes (Figure 6A),
which was totally impaired by either latrunculin
(Figure 6C) or blebbistatin (Figure 6E). As depicted in
Figure 6D and F, similar inhibitory effects were
achieved after depletion of HuR (Supplementary Figure
S5) or myosinIIA (Figure 1B) by speciﬁc siRNAs.
AngII induces a physical interaction of HuR with myosin
IIA, which depends on the C-terminal RRM 3 and on
HuR phosphorylation at S318
In a next approach, we determined whether AngII may
induce a physical interaction of HuR with the motor
protein myosin IIA. For this purpose, we used pull-
down assays with cell lysates from HMC expressing
different c-myc-HuR constructs bearing wild-type HuR,
or different truncations in HuR as summerized in
Figure 7A. IP of c-myc-HuR fusion proteins with an
anti-c-myc antibody speciﬁcally coprecipitated a protein
of  230kDa corresponding to the molecular weight of
myosin IIA in cell lysates from AngII-stimulated HMC
(Figure 7A). In contrast, myosin IIA was not precipitated
if lysates from untreated cells were used for IP indicating a
stimulus-dependent HuR interaction with myosin IIA
(Figure 7A). Structurally, HuR and its neuronal relatives
Figure 5. AngII-induced HuR redistribution between non-polysomal RNPs and polysomes depends on the actin–myosin based cytoskeleton.
(A). Serum-deprived HMC were treated for 2h with vehicle ( ) or with AngII in the absence or presence of latrunculin (Lat. A) or blebbistatin
(Blebbistat.), which were applied for 30min (Lat. A) or 4h (Blebbistat.) before AngII stimulation. Thereafter, cells were lyzed for separation of total
polysomes from post-polysomal RNPs (RNPs) by ultracentrifugation and HuR distribution in both fractions determined by immunoblotting. (A, left
panel). Before ultracentrifugation, cells were either lyzed in the absence ( ) or in the presence of EDTA (A, right panel). (B). HMC were either
transfected with control siRNA (siRNA-control) or with siRNA of myosin heavy chain 9 (siRNA-MYH9). Seventy-two hours after transfection, cells
were serum starved and stimulated for further 2h with vehicle ( ) or AngII (+). The efﬁciency of silencing of myosin IIA is proven by western blot
analysis. In parallel, cells were extracted for total polysomes and non-polysomal RNP particles, before HuR distribution in the different fractions was
assessed by Western blotting. The blots shown are from a single experiment representative of two repeats with similar results. (right panel).
Stimulation with AngII for 2h induces a total redistribution of Flag-tagged HuR from RNPs to polysomes.
10 Nucleic AcidsResearch, 2013contain three highly conserved RRMs and a less
conserved hinge region, which bears the HNS relevant
for nucleo-cytoplasmic HuR shuttling and which further-
more separates the two N-terminal RRMs (RRM1 and 2)
from the C-terminal RRM3 (10,39). To further delineate
which of these HuR domains is implicated in myosin
binding, we compared the potential binding of a series
of c-myc-tagged HuR truncations (32) with endogenous
myosin in the cell lysates of different c-myc-HuR trans-
fectants shown in Figure 7A. Importantly, myosin binding
to c-myc-tagged HuR was totally lost in cells expressing a
RRM3 truncated HuR mutant or c-myc-HuRHinge
Figure 6. AngII-induced COX-2 mRNA redistribution between RNPs and polysomes depends on the actin-myosin based cytoskeleton. Effects of
microﬁlament inhbitors (C and E) or siRNA transfections (B, D and F) on the AngII-induced RNP-polysomal COX-2 mRNA redistribution.
Polysomes were separated from free RNPs as described in ‘Materials and Methods’ section, before RNA from both fractions was isolated and
levels of COX-2 mRNA were measured by qRT-PCR. (A, C and E). Serum starved HMC were preincubated for 16h with a cytokine-mix of IL-1b
and TNFa (both at 2nM) before stimulated for further 2h in the presence (ﬁlled bars) or absence (open bars) of AngII without (+vehicle) or with
the indicated inhibitors, which were given 4h before administration of AngII. (B, D and F). HMC were either treated with control siRNA (siRNA-
control), siRNA speciﬁc for HuR (siRNA-HuR) or myosin heavy chain 9 (siRNA-MYH9) for 72h before cells were stimulated for 16h with the
cytokine-mix in the presence (ﬁlled bars) or absence (open bars) of AngII, which was added 2h before cell lysis. Results show the stimulus dependent
changes in COX-2 mRNA content within the indicated fractions relative to total cellular COX-2 mRNA contents. Data are means±SD of three
independent experiments and depicted as relative COX-2 mRNA distribution., ***P<0.005 versus control conditions.
Nucleic Acids Research, 2013 11Figure 7. AngII promotes a physical interaction of HuR with non-muscle myosin IIA, which structurally depends on phosphorylated S318 within
the RRM3. (A, upper panel). Schematic representation of c-myc-tagged wild-type HuR and different deletion mutants bearing truncations in the
speciﬁc HuR domains. (A, lower panel). HMC were transfected with the indicated c-myc-HuR coding plasmids. Seventy-two hours after transfection,
cells were treated without ( ) or with AngII (+) for 2h. Thereafter, c-myc-tagged HuR proteins were immunoprecipitated with an anti-c-myc
antibody (IP: c-myc), or isotype speciﬁc control (IP: IgG). HuR-bound myosin IIA was detected by Western blot analysis with an anti-myosin IIA
speciﬁc antibody. Equal pull-down (input levels) of c-myc was ascertained by reincubating the blot with the same antibody used for IP. (B). Blot-
overlay assay demonstrating that the hinge region of HuR is not relevant for AngII-induced myosin IIA binding. Pull-down of myosin IIA from
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(continued)(Figure 7A). As the loss in myosin binding observed with
the HuRHinge mutant may simply result from an im-
paired nucleo-cytoplasmic HuR transport, we performed
a blot overlay assay as an alternative approach, which
independent of the subcellular HuR distribution, allows
detection of interactions between ectopically expressed
HuR proteins and endogenous myosin IIA. Thereby,
myosin was immunoprecipitated from total lysates of un-
treated HMC, and the bound proteins were resolved by
denaturating SDS–PAGE. As shown in Figure 7B, we
observed a strong immunopositive myosin IIA band
when the membranes were incubated with the cell lysates
from AngII-treated transfectants independent of whether
cells were transfected with a wild-type or mutated HuR
construct (c-myc-HuRHinge) with a truncated HNS.
These results clarly indicate that the hinge region of
HuR in contrast to the RRM3 is irrelevant for myosin
IIA binding.
Next, we tested the impact of HuR phosphorylation at
Ser 318, which is critical for AngII-induced HuR binding
to the AREs of target mRNA (16). Interestingly, AngII-
induced myosin binding to the phosphorylation deﬁcient
HuR bearing a serine-to-alanine substitution at position
318 (c-myc-S318AHuR) was totally impaired (Figure 7C),
and, conversely, a stimulus-dependent myosinIIA binding
was observed with a phosphomimetic S318 to Asp HuR
protein (c-myc-S318DHuR). According to the critical
impact of Ser 318 for mRNA binding, the afﬁnity of
wild-type HuR to myosin IIA was completely abrogated
if cell lysates had been treated with RNase A, indicating
that the AngII-induced HuR interaction with myosin
IIA critically depends on RNA bound status of HuR
(Figure 7D, left panel). Similar to the ﬁndings with
ectopic HuR proteins, an AngII-induced interaction
of myosin was also observed for endogenous HuR
(Figure 7D, right panel).
DISCUSSION
According to a validated model of cytoplasmic mRNA
trafﬁcking, translationally silent mRNAs are assembled
with various trans-acting RNA-binding proteins into an
export competent RNP, which is ready for transit through
the nuclear pore complex. Thereby, RNPs, once they have
passedthenucleus,canassociatewithcytoskeletal elements
and guide cytoplasmic RNA to its speciﬁc destination
(22,23,40). However, the mechanisms that speciﬁcally
control stimulus dependent temporal changes in the
docking and release of RNPs from the cytoskeleton are
unknown. A microtubule dependent transport of neuronal
ELAV proteins is necessary for an association with mRNA
tosmallmRNPgranulesanditssubsequenttargetingtothe
translation apparatus (26). A microtubule dependent
trafﬁcking is furthermore implied in the fast and long-
distance mRNA transport in neurons and oocytes
(24,41–43). In contrast to these reports, a microtubule-
mediated transport seems irrelevant for HuR. Here, we
have identiﬁed the involvement of an actin-myosin IIA-
based mechanism as indicated by the strong inhibitory
effects by latrunculin A and blebbistatin (Figure 1A) and
byexperimentswithmyosinIIAspeciﬁcsiRNA(Figure1B).
ThereductionincytoplasmicHuRinAngIIpluslatrunculin
treated cells suggests that the lack of cytoplasmic HuR is a
direct consequence of abrogated nuclear HuR export to the
cytoplasm after microﬁlament disruption and implies a
microﬁlament-mediated cross-talk between both compart-
ments. A cytoskeleton-dependent communication between
the nucleus and the cytoplasm has been demonstrated by
various studies (44–47). It is noteworthy that the actin
polymerizing protein proﬁlin is critical for a Ran-
mediatedexportinDrosophila(48),whichisalsoimplicated
in nucleo-cyoplasmic HuR shuttling (47).
Given the fact that HuR co-sedimented exclusively with
the free and cytoskeleton bound polysomes after cells were
Figure 7. Continued
vehicle ( ) or AngII treated HMC was performed as described in ‘Materials and Methods’ section. Blots were probed with equal amounts of total
cell lysates cells overexpressing c-myc-HuR wild-type or c-myc-HuRHinge. Myosin IIA-HuR interaction was assessed by reincubating the blot with
an anti-c-myc antibody. Equal pull-down of myosin is ascertained by reincubating the blot with the same antibody used for the myosin IIA co-IP.
(C). HMC were transfected with the indicated c-myc-point mutated HuR and IPs were performed similar as described for (A). Equal pull-down
(input levels) of c-myc was ascertained by reincubating the blot with the same antibody used for IP. (D, left panel). HuR binding to myosin IIA is
sensitive toward RNase treatment. HMC overexpressing c-myc-HuRwild-type or c-myc-HuRHinge were treated for 2h with AngII (0.1mM) before
total cell lysates from transfectants were immunoprecipitated with an anti-c-myc antibody or with control IgG. Before the IP reaction, the cell
homogenates were subjected to RNase treatment and subsequently immunoblotted with an anti-myosin IIA speciﬁc antibody. Equal pull-down of c-
myc is ascertained by reincubating the blot with anti-c-myc antiserum. (right panel). To test for AngII-dependent association of myosinIIA with
endogenous HuR, 200mg of total cell extracts from unstimulated ( ) or AngII-stimulated (+) HMC were subjected to (IP) as described in ‘Materials
and Methods’ section. The data shown are from a single experiment representative of two repeats with similar results.
Nucleic Acids Research, 2013 13stimulated with AngII (Figure 4A and C) indicates that
AngII-activated HuR is preferentially transported to
translationally active cell compartments. Further studies
are needed to elucidate the general impact of a speciﬁc
external stimulus to the allocation of HuR to a speciﬁc
polysomal subfraction. Functionally, the AngII-induced
accumulation of HuR in speciﬁc subpolysomal fractions
is consistent with a stimulus-dependent appearance of
COX-2 mRNA within the same fractions (Figure 4B).
The ﬁnding that the AngII-induced HuR association to
polysomes is totally lost if cell lysates were treated with
phosphatase or RNase implicates that both RNA binding
and phosphorylation of HuR are indispensable for the
recruitment of HuR to polysomes (Figure 4A, right
panel). This notion is further conﬁrmed by the observation
that the co-sedimentation of Flag-tagged phosphomimetic
S318D HuR with cytoskeleton bound and free polysomes
remained unaffected by phosphatase treatment but still
sensitive toward RNase (Figure 4C). As S318 is a func-
tional PKCd phosphorylation site, which is critical for
AngII-induced HuR binding to speciﬁc target mRNAs
(16), results with a corresponding phosphorylation deﬁ-
cient HuR mutation strongly suggest that HuR binding
to target mRNA is critical for its redistribution from
RNPs to translational active polysomes. Similar to HuR
recruitment to polysomes, myosin IIA association with
HuR is a phosphorylation and RNA-dependent event.
Accordingly, AngII-induced physical interaction of
myosin II with HuR was totally impaired in HuR
bearing a serine-to-alanine substitution at position 318
in the RRM3 (Figure 7C). In addition, mapping of
putative myosin-binding domains revealed that the
C-terminal RRM3 is critical for myosin IIA binding
(Figure 7A and B). The fact that phosphorylation at
S318 in the RRM3 is critical for AngII-induced RNA-
binding of HuR (16) as well as for myosin binding
clearly indicates that the RNA-bound status of HuR is
indispensable for its association with nonmuscle myosin.
Further studies are needed to elucidate whether HuR does
directly interact with myosin IIA or, whether alternatively,
the interaction is indirect and bridged by either an ancil-
lary RNA-binding protein and/or is directly mediated
through HuR-bound mRNA. Consequently, our data
propose an active role of phosphorylated HuR in the an-
chorage and active transport of ARE-bearing mRNA
species to microﬁlaments through stimulus-induced
myosin binding. Collectively, our study implicates that
mRNA binding, nuclear export and subsequent cytoplas-
mic trafﬁcking of HuR and its cargo mRNA comprise an
intimately linked series of events that are initiated and
coordinated via nuclear HuR phosphorylation at S318
(Figure 8). The discovery of an actin-myosin involvement
in HuR-directed mRNA trafﬁcking furthermore empha-
sizes the pharmacological potential of latrunculin and
Figure 8. Schematic summary of regulation of HuR trafﬁcking by the actin-myosin cytoskeleton. AngII triggers nuclear translocation of the PKCd,
which in turn phosphorylates nuclear HuR at RRM3, thereby increasing HuR binding to target mRNAs. The HuR-bound mRNA assembles to a
motile transport RNP particle and is exported to the cytoplasm by a mechanism, which essentially requires the actin-myosin-based cytoskeleton.
HuR and bound cargo-mRNA is directed to speciﬁc cytoplasmic destinations via a myosin-driven transport along ﬁlamentous (F) actin. Importantly,
the AngII-induced recruitment of HuR from translation inactive RNPs to FP and CBP occurs via an interaction of HuR with myosin IIA, which is
highly sensitive toward RNase and PPtase treatment. AngII=angiotensin II, CBP=cytoskeleton bound polysomes, FP=free polysomes,
PKCd=protein kinase Cd, PPtase=protein phosphatase, RNP=ribonucleoprotein, RRM=RNA recognition motif, 30UTR=30untranslated
region.
14 Nucleic AcidsResearch, 2013its semisynthetic derivatives to interfere with
posttranscriptional gene regulation by the multifunctional
protein HuR.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors are grateful to Ann-Bin Shyu (University of
Texas Medical School, Houston) for providing the Myc-
tagged HuR plasmids and to Heinfried Radeke (Goethe
University of Frankfurt, Germany) for providing primary
human mesangial cells (HMC).
FUNDING
German Research Foundation (DFG) [EB 257/5-1,
GRK1172, SFB 815]; the state of Hesse (Onkogene
Signaltransduktion [L-4-518/55.004]); and the Excellence
Cluster ‘Cardiopulmonary System (ECCPS)’ EXC 147/2.
Funding for open access charge: DFG [EB 257/5-1].
Conﬂict of interest statement. None declared.
REFERENCES
1. Myer,V.E., Fan,X.C. and Steitz,J.A. (1997) Identiﬁcation of HuR
as a protein implicated in AUUUA-mediated mRNA decay.
EMBO J., 16, 2130–2139.
2. Fan,X.C. and Steitz,J.A. (1998) Overexpression of HuR, a
nuclear-cytoplasmic shuttling protein, increases the in vivo
stability of ARE-containing mRNAs. EMBO J., 17, 3448–3460.
3. Keene,J.D. (1999) Why is Hu where? Shuttling of early-response-
gene messenger RNA subsets. Proc. Natl Acad. Sci. USA, 96,
5–7.
4. Zhu,H., Zhou,H.L., Hasman,R.A. and Lou,H. (2007) Hu proteins
regulate polyadenylation by blocking sites containing U-rich
sequences. J. Biol. Chem., 282, 2203–2210.
5. Izquierdo,J.M. (2008) Hu antigen R (HuR) functions as an
alternative pre-mRNA splicing regulator of Fas apoptosis-
promoting receptor on exon deﬁnition. J. Biol. Chem., 283,
19077–19084.
6. Meisner,N.C. and Filipowicz,W. (2011) Properties of the
regulatory RNA-binding protein HuR and its role in controlling
miRNA repression. Adv. Exp. Med. Biol., 700, 106–123.
7. Abdelmohsen,K. and Gorospe,M. (2010) Posttranscriptional
regulation of cancer traits by HuR. Wiley Interdiscip. Rev. RNA,
1, 214–229.
8. Khabar,K.S. (2010) Post-transcriptional control during chronic
inﬂammation and cancer: a focus on AU-rich elements. Cell. Mol.
Life Sci., 67, 2937–2955.
9. Pascale,A. and Govoni,S. (2012) The complex world of post-
transcriptional mechanisms: is their deregulation a common link
for diseases? Focus on ELAV-like RNA-binding proteins. Cell.
Mol. Life Sci., 69, 501–517.
10. Fan,X.C. and Steitz,J.A. (1998) HNS, a nuclear-cytoplasmic
shuttling sequence in HuR. Proc. Natl Acad. Sci. USA, 95,
15293–15298.
11. Abdelmohsen,K., Pullmann,R. Jr, Lal,A., Kim,H.H., Galban,S.,
Yang,X., Blethrow,J.D., Walker,M., Shubert,J., Gillespie,D.A.
et al. (2007) Phosphorylation of HuR by Chk2 regulates SIRT1
expression. Mol. Cell, 25, 543–557.
12. Kim,H.H., Abdelmohsen,K., Lal,A., Pullmann,R. Jr, Yang,X.,
Galban,S., Srikantan,S., Martindale,J., Blethrow,J., Shokat,K.M.
et al. (2008) Nuclear HuR accumulation through phosphorylation
by Cdk1. Genes Dev., 22, 1804–1815.
13. Doller,A., Huwiler,A., Mu ¨ ller,R., Radeke,H.H., Pfeilschifter,J.
and Eberhardt,W. (2007) Protein kinase Ca-dependent
phosphorylation of the mRNA-stabilizing factor HuR:
implications for posttranscriptional regulation of
cyclooxygenase-2. Mol. Biol. Cell, 18, 2137–2148.
14. Amadio,M., Bucolo,C., Leggio,G.M., Drago,F., Govoni,S. and
Pascale,A. (2010) The PKCb/HuR/VEGF pathway in diabetic
retinopathy. Biochem. Pharmacol., 80, 1230–1237.
15. Doller,A., Akool,el-S., Huwiler,A., Mu ¨ ller,R., Radeke,H.H.,
Pfeilschifter,J. and Eberhardt,W. (2008) Posttranslational
modiﬁcation of the AU-rich element binding protein HuR by
protein kinase Cd elicits angiotensin II-induced stabilization and
nuclear export of cyclooxygenase 2 mRNA. Mol. Cell. Biol., 28,
2608–2625.
16. Doller,A., Schlepckow,K., Schwalbe,H., Pfeilschifter,J. and
Eberhardt,W. (2010) Tandem phosphorylation of serines 221 and
318 by protein kinase Cd coordinates mRNA-binding and
nucleocytoplasmic shuttling of HuR. Mol. Cell. Biol., 30,
1397–1410.
17. Gallouzi,I.E., Brennan,C.M. and Steitz,J.A. (2001) Protein ligands
mediate the CRM1-dependent export of HuR in response to heat
shock. RNA, 7, 1348–1361.
18. Rebane,A., Aab,A. and Steitz,J.A. (2004) Transportins 1 and 2
are redundant nuclear import factors for hnRNP A1 and HuR.
RNA, 10, 590–599.
19. Gu ¨ ttinger,S., Mu ¨ hlha ¨ usser,P., Koller-Eichhorn,R., Brennecke,J.
and Kutay,U. (2004) Transportin2 functions as importin and
mediates nuclear import of HuR. Proc. Natl Acad. Sci. USA,
101, 2918–2923.
20. Wang,W., Yang,X., Kawai,T., Lo ´ pez de Silanes,I., Mazan-
Mamczarz,K., Chen,P., Chook,Y.M., Quensel,C., Ko ¨ hler,M. and
Gorospe,M. (2004) AMP-activated protein kinase-regulated
phosphorylation and acetylation of importin a1: involvement in
the nuclear import of RNA-binding protein HuR. J. Biol. Chem.,
279, 48376–48388.
21. Hovland,R., Hesketh,J.E. and Pryme,I.F. (1996) The
compartmentalization of protein synthesis: importance of
cytoskeleton and role in mRNA targeting. Int. J. Biochem. Cell
Biol., 28, 1089–1105.
22. Jansen,R.P. (1999) RNA-cytoskeletal associations. FASEB J., 13,
455–466.
23. Kindler,S., Wang,H., Richter,D. and Tiedge,H. (2005) RNA
transport and local control of translation. Annu. Rev. Cell Dev.
Biol., 21, 223–245.
24. Martin,K.C. and Ephrussi,A. (2009) mRNA localization: gene
expression in the spatial dimension. Cell, 136, 719–730.
25. Brendza,R.P., Serbus,L.R., Duffy,J.B. and Saxton,W.M. (2000) A
function for kinesin I in the posterior transport of oskar mRNA
and Staufen protein. Science, 289, 2120–2122.
26. Antic,D. and Keene,J.D. (1998) Messenger ribonucleoprotein
complexes containing human ELAV proteins: interactions with
cytoskeleton and translational apparatus. J. Cell Sci., 111,
183–197.
27. Fujiwara,Y., Kasashima,K., Saito,K., Fukuda,M., Fukao,F.,
Sasano,Y., Inoue,K., Fujiwara,T. and Sakamoto,H. (2011)
Microtubule association of a neuronal RNA-binding protein HuD
through its binding to the light chain of MAP1B. Biochimie, 93,
817–822.
28. Radeke,H.H., Meier,B., Topley,N., Flo ¨ ge,J., Habermehl,G.G. and
Resch,K. (1990) Interleukin 1-b and tumor necrosis factor-a
induce oxygen radical production in mesangial cells. Kidney Int.,
37, 767–775.
29. Hovland,R., Campbell,G., Pryme,I. and Hesketh,J. (1995) The
mRNAs for cyclin A, c-myc and ribosomal proteins L4 and S6
are associated with cytoskeletal-bound polysomes in HepG2 cells.
Biochem. J., 310, 193–196.
30. Schaefer,M., Albrecht,N., Hofmann,T., Gudermann,T. and
Schultz,G. (2001) Diffusion-limited translocation mechanism of
protein kinase C isotypes. FASEB J., 15, 1634–1636.
31. Doller,A., Winkler,C., Azrilian,I., Schulz,S., Hartmann,S.,
Pfeilschifter,J. and Eberhardt,W. (2011) High-constitutive HuR
Nucleic Acids Research, 2013 15phosphorylation at Ser 318 by PKCd propagates tumor relevant
functions in colon carcinoma cells. Carcinogenesis, 32, 676–685.
32. Chen,C.Y., Xu,N. and Shyu,A.B. (2002) Highly selective actions
of HuR in antagonizing AU-rich element-mediated mRNA
destabilization. Mol. Cell. Biol., 22, 7268–7278.
33. Schreiber,E., Matthias,P., Mu ¨ ller,M.M. and Schaffner,W. (1989)
Rapid detection of octamer binding proteins with ‘mini-extracts’,
prepared from a small number of cells. Nucleic Acids Res., 17,
6419.
34. Co ˆ te ´ ,J. and Richard,S. (2005) Tudor domains bind symmetrical
dimethylated arginines. J. Biol. Chem., 280, 28476–28483.
35. Kova ´ cs,M., To ´ th,J., Hete ´ nyi,C., Ma ´ lna ´ si-Csizmadia,A. and
Sellers,J.R. (2004) Mechanism of blebbistatin inhibition of myosin
IIA. J. Biol. Chem., 279, 35557–35563.
36. Mermall,V., Post,P.L. and Mooseker,M.S. (1998) Unconventional
myosins in cell movement, membrane trafﬁc, and signal
transduction. Science, 279, 527–533.
37. Abdelmohsen,K., Srikantan,S., Yang,X., Lal,A., Kim,H.H.,
Kuwano,Y., Galban,S., Becker,K.G., Kamara,D., de Cabo,R.
et al. (2009) Ubiquitin-mediated proteolysis of HuR by heat
shock. EMBO J., 28, 1271–1282.
38. Zhou,H.L., Geng,C., Luo,G. and Lou,H. (2013) The p97-UBXD8
complex destabilizes mRNA by promoting release of
ubiquitinated HuR from mRNP. Genes Dev., 27, 1046–1058.
39. Good,P.J. (1995) A conserved family of elav-like genes in
vertebrates. Proc. Natl Acad. Sci. USA, 92, 4557–4561.
40. Daneholt,B. (2001) Assembly and transport of a premessenger
RNP particle. Proc. Natl Acad. Sci. USA, 98, 7012–7017.
41. Wilhelm,J.E. and Vale,R.D. (1993) RNA on the move: the
mRNA localization pathway. J. Cell Biol., 123, 269–274.
42. Czaplinski,K. and Singer,R.H. (2006) Pathways for mRNA
localization in the cytoplasm. Trends Biochem. Sci., 31,
687–693.
43. Sotelo-Silveira,J.R., Calliari,A., Kun,A., Koenig,E. and
Sotelo,J.R. (2006) RNA trafﬁcking in axons. Trafﬁc, 7, 508–515.
44. Schindler,M. and Jiang,L.W. (1986) Nuclear actin and myosin as
control elements in nucleocytoplasmic transport. J. Cell Biol.,
102, 859–862.
45. Zhang,S., Buder,K., Burkhardt,C., Schlott,B., Go ¨ rlach,M. and
Grosse,F. (2002) Nuclear DNA helicase II/RNA helicase A binds
to ﬁlamentous actin. J. Biol. Chem., 277, 843–853.
46. Zhang,S., Ko ¨ hler,C., Hemmerich,P. and Grosse,F. (2004) Nuclear
DNA helicase II (RNA helicase A) binds to an F-actin
containing shell that surrounds the nucleolus. Exp. Cell Res., 293,
248–258.
47. Tretyakova,I., Zolotukhin,A.S., Tan,W., Bear,J., Propst,F.,
Ruthel,G. and Felber,B.K. (2005) Nuclear export factor family
protein participates in cytoplasmic mRNA trafﬁcking. J. Biol.
Chem., 280, 31981–31990.
48. Minakhina,S., Myers,R., Druzhinina,M. and Steward,R. (2005)
Crosstalk between the actin cytoskeleton and Ran-mediated
nuclear transport. BMC Cell Biol., 6, 32.
49. Brennan,C.M., Gallouzi,I.E. and Steitz,J.A. (2000) Protein ligands
to HuR modulate its interaction with target mRNAs in vivo.
J. Cell Biol., 151, 1–14.
16 Nucleic AcidsResearch, 2013